For how we live.
One in five people get chronic itch at some point. When no rash and no cause turn up, a Cochrane review found almost no trials at all — leaving guideline experts to work from indirect evidence.
Rezpegaldesleukin works by expanding the immune system's regulatory T cells rather than blocking an inflammatory signal — a new mechanism for atopic dermatitis, tested so far only in a phase 2b study.
In the two pivotal dupilumab trials, 36% to 38% reached that endpoint at 16 weeks against 8% to 10% on placebo. A 97-trial network review finds the newer drugs clustered closely together.